Moreover, there is solid evidence of dasatinib being used for BC treatment (including TNBC, ER-negative BC, and ER+/PR+/HER2 + BC or metastatic BC), including several clinical studies [45,46,47]. Here, ERBB2 is linked to breast cancer.